
| • |
Announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC with additional participation from current investors.
|
| o |
The PIPE includes a contingent milestone closing triggered by the Company’s submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with
NantWorks, subject to the satisfaction or waiver of applicable closing conditions.
|
| o |
In connection with the PIPE, the Company entered into an option agreement granting NantWorks, LLC a one-year exclusive right to negotiate an exclusive license for the PDS0101 program.
|
| o |
Dr. Patrick Soon-Shiong, founder of NantWorks, and James Banaag appointed to the Company’s Board of Directors as Nant Capital designees.
|
| • |
Appointed three pharma veterans to the Company’s Board of Directors, effective October 18, 2026:
|
| o |
John Dawson CBE, Deborah Ramsdell, and Bruce Wendel bring deep corporate development, commercialization, and regulatory expertise to the Company.
|

| • |
Hosted a Key Opinion Leader (KOL) event discussing PDS0301 Phase 2 trials and projected clinical progress.
|
| o |
The event featured Jonathan M. Hernandez, M.D., an investigator with the Surgical Oncology Program at the National Cancer
Institute’s Center for Cancer Research. Dr. Hernandez joined company management to discuss clinical outcomes from PDS0301 in the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC)
cohort.
|
| o |
A replay of the event is available here.
|
| • |
Announced publication of VERSATILE-002 Phase 2 clinical trial results of PDS0101 with pembrolizumab in
HPV16-positive recurrent and/or metastatic (R/M) head and neck cancer in JAMA Oncology.
|
| • |
Received issuance of a Japanese patent, JP Patent No.7909860, titled Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes. The patent broadly covers
compositions and use of the Versamune® technology platform broadly for use as a T cell activating immunotherapy. A related US patent, US Patent No. 12,551,460, issued earlier in 2026.
|
| • |
Received issuance of patents titled HPV16 Non-HLA Restricted T Cell vaccines, Compositions and Methods of Use Thereof in both India and Israel, IN Patent No. 603830 and IL Patent No. 265833. The
patents cover the composition and use of PDS0101 being developed to treat HPV16-positive cancers. A related US patent, US Patent No. 11,401,306, issued in 2022.
|




|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development expenses
|
$
|
2,051,213
|
$
|
4,576,389
|
$
|
8,773,832
|
$
|
14,620,308
|
||||||||
|
General and administrative expenses
|
3,844,891
|
3,563,753
|
10,140,094
|
10,248,943
|
||||||||||||
|
Total operating expenses
|
5,896,104
|
8,140,142
|
18,913,926
|
24,869,251
|
||||||||||||
|
Loss from operations
|
(5,896,104
|
)
|
(8,140,142
|
)
|
(18,913,926
|
)
|
(24,869,251
|
)
|
||||||||
|
Interest income (expense)
|
||||||||||||||||
|
Interest income
|
41,630
|
281,109
|
353,850
|
992,582
|
||||||||||||
|
Interest expense
|
(1,766,451
|
)
|
(1,150,378
|
)
|
(6,160,480
|
)
|
(4,225,737
|
)
|
||||||||
|
Interest income (expense), net
|
(1,724,821
|
)
|
(869,269
|
)
|
(5,806,630
|
)
|
(3,233,155
|
)
|
||||||||
|
Loss before income taxes
|
(7,620,925
|
)
|
(9,009,411
|
)
|
(24,720,556
|
)
|
(28,102,406
|
)
|
||||||||
|
Benefit from income taxes
|
-
|
-
|
-
|
1,169,820
|
||||||||||||
|
Net loss and comprehensive loss
|
(7,620,925
|
)
|
(9,009,411
|
)
|
(24,720,556
|
)
|
(26,932,586
|
)
|
||||||||
|
Per share information:
|
||||||||||||||||
|
Net loss per share, basic and diluted
|
$
|
(0.11
|
)
|
$
|
(0.19
|
)
|
$
|
(0.40
|
)
|
$
|
(0.60
|
)
|
||||
|
Weighted average common shares outstanding basic and diluted
|
71,936,955
|
46,869,531
|
61,145,055
|
44,648,508
|
||||||||||||

|
September 30,
|
December 31,
|
|||||||
|
2026
|
2025
|
|||||||
|
Cash and cash equivalents
|
$
|
15,245,081
|
$
|
26,711,969
|
||||
|
Working capital
|
13,297,920
|
18,770,871
|
||||||
|
Total assets
|
18,571,942
|
30,494,083
|
||||||
|
Long term debt
|
-
|
11,733,350
|
||||||
|
Accumulated deficit
|
(241,327,060
|
)
|
(216,606,504
|
)
|
||||
|
Total stockholders’ equity
|
13,495,140
|
9,251,833
|
||||||